Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | CD134 |
| Synonyms | Tumor necrosis factor receptor superfamily member 4; OX40 antigen; OX40L receptor; Ox40; Txgp1; Tnfrsf4 |
| Location | Membrane |
| Accession | P47741 |
| Clone Number | S-R711 |
| Antibody Type | Rat mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Ms |
| Purification | Protein G |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 25% Glycerol, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5 μl per million cells in 100μl volume |
Background
CD134, also known as TNFRSF4 or OX40, is a member of the tumor necrosis factor receptor superfamily. It is a co-stimulatory molecule primarily expressed on activated CD4+ and CD8+ T cells, as well as other immune cells such as natural killer (NK) cells and dendritic cells. Structurally, CD134 contains four TNFR-Cys repeats and interacts with its ligand, OX40L (TNFSF4), to activate downstream signaling pathways, including the NF-κB pathway through adaptor proteins like TRAF2 and TRAF5. This interaction promotes T cell proliferation, cytokine production, and enhances the survival of CD8+ T cells, playing a crucial role in immune responses. Additionally, CD134 has been implicated in various diseases, including cancer and autoimmune conditions, making it a target for immunotherapy and other therapeutic interventions.
